Journal of Oncology

Strategies to Improve Cancer Immunotherapy


Publishing date
01 Jan 2019
Status
Published
Submission deadline
31 Aug 2018

Lead Editor
Guest Editors

1Johns Hopkins University, Baltimore, USA

2Washington University in St. Louis, St. Louis, USA


Strategies to Improve Cancer Immunotherapy

Description

Traditional cancer treatment includes chemotherapy and radiation treatment, often associated with severe complication. Recently, the development of next generation of sequencing technology revealed many cancer driving mutations that facilitate the development of small molecular inhibitors to specifically target these oncoproteins. It significantly reduced systematic toxicity. However, many oncogenes still cannot be directly targeted by drugs, such as mutant KRAS; also cancers always come back after prolonged treatment due to acquired resistance in cancer cells. Recently, the advancement of cancer immunotherapy, specifically the development of immune checkpoint blockade and CAR T cells, revolutionized the way we treat cancers. It is designed to harness the patient’s own immune system to specifically target tumor cells and already demonstrated durable clinical responses in many patients even with advanced-stage malignancies.

However, tumor cells often induce an immunosuppressive microenvironment, which includes the development of immunosuppressive populations of immune cells, such as myeloid-derived suppressor cells and regulatory T cells; cytokines, such as transforming growth factor-β (TGF-β) and IL-10; metabolic byproducts, such as indole amine 2,3-dioxygenase (IDO) and lactic acid; and inhibitory immune checkpoint molecules, such as programmed cell death ligand 1 (PD-L1). Understanding the complexity of immunomodulation by tumors is important for the development of efficient immunotherapy. Various strategies are being developed to enhance antitumor immune responses, including cancer vaccines, inhibitors for immune checkpoints blockade, and combination of immunotherapy with other currently existing therapies, such as epigenetic therapy and chemotherapy/radiation therapy.

Several recent molecular studies and clinical trials also demonstrated that there is big variability in the ability of a tumor to induce an immune response. Therefore, the major aim of this proposed special issue is to discuss the recent innovations and advances in understanding of various aspects of tumor immune response and discovery of novel determinants of tumor immunogenicity for predicting or modulating responses to immunotherapy. We invite original research papers and clinical studies focused on various aspects of cancer immunotherapy and also welcome review articles that describe any of the topics related to cancer immunotherapy.

Potential topics include but are not limited to the following:

  • Molecular mechanisms of immune escape of different types of cancers
  • The contribution of tumor microenvironment, epithelial to mesenchymal transition (EMT), and metabolism to tumor immune response
  • Development of novel biomarkers to predict immunotherapy response
  • Development of animal models for studying cancer immunotherapy
  • New treatment regimens for improving immunotherapy efficiency, such as combination of chemotherapy and/or radiotherapy with immune checkpoint inhibitors or CAR T, and development of novel cancer vaccine in immunotherapy
  • The benefit and potential adverse effects of immunotherapy in clinical treatment of different types of cancers

Articles

  • Special Issue
  • - Volume 2019
  • - Article ID 6230409
  • - Review Article

Clinical Spectrum of Complications Induced by Intravesical Immunotherapy of Bacillus Calmette-Guérin for Bladder Cancer

Yuqing Liu | Jian Lu | ... | Lulin Ma
  • Special Issue
  • - Volume 2019
  • - Article ID 7035045
  • - Review Article

Current and Emerging Targets in Immunotherapy for Osteosarcoma

Shinji Miwa | Toshiharu Shirai | ... | Hiroyuki Tsuchiya
  • Special Issue
  • - Volume 2018
  • - Article ID 2937012
  • - Research Article

Automated Tumour Recognition and Digital Pathology Scoring Unravels New Role for PD-L1 in Predicting Good Outcome in ER-/HER2+ Breast Cancer

Matthew P. Humphries | Sean Hynes | ... | Niamh E. Buckley
  • Special Issue
  • - Volume 2018
  • - Article ID 7946021
  • - Research Article

Secretory High-Mobility Group Box 1 Protein Affects Regulatory T Cell Differentiation in Neuroblastoma Microenvironment In Vitro

Thitinee Vanichapol | Wararat Chiangjong | ... | Suradej Hongeng
  • Special Issue
  • - Volume 2018
  • - Article ID 9732939
  • - Review Article

Transforming of the Tumor Microenvironment: Implications for TGF- Inhibition in the Context of Immune-Checkpoint Therapy

Stefanie Löffek
  • Special Issue
  • - Volume 2018
  • - Article ID 3979527
  • - Research Article

Exploration of the Combination of PLK1 Inhibition with Immunotherapy in Cancer Treatment

Mengyuan Li | Zhixian Liu | Xiaosheng Wang
  • Special Issue
  • - Volume 2018
  • - Article ID 8653489
  • - Review Article

Immunomodulatory Effects of Drugs for Effective Cancer Immunotherapy

Maiko Matsushita | Mai Kawaguchi
  • Special Issue
  • - Volume 2018
  • - Article ID 6279871
  • - Review Article

Clinical and Molecular Characteristics Associated with Survival in Advanced Melanoma Treated with Checkpoint Inhibitors

Sunil Badami | Sunil Upadhaya | ... | Ghassan Bachuwa
Journal of Oncology
 Journal metrics
Acceptance rate33%
Submission to final decision93 days
Acceptance to publication48 days
CiteScore3.220
Impact Factor2.600
 Submit